Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The European Union Allocates Six Million Euros to Study Prevention Strategies Tumors Caused by HPV

Published: Tuesday, November 05, 2013
Last Updated: Tuesday, November 05, 2013
Bookmark and Share
The human papillomavirus (HPV) is responsible for cervical cancer and is behind a significant percentage of other tumors such as vulva , vagina, penis, anus, and oropharynx.

It is estimated that, in Europe , every year 30,000 women die as a result of cervical cancer, especially in the Eastern countries , where screening programs are not consolidated.

The consortium CoheaHr wants to provide scientific evidence for the clinical effectiveness and cost - effectiveness of different strategies to prevent cervical cancer throughout the European Union. To assess strategies focus on screening for HPV detection and vaccination. Specifically, the consortium conducted four clinical trials:

•    Compare the results of sampling for HPV testing when performed by the patient herself and when you get a health care professional, and their possible implementation as a method to increase screening coverage.
•    To determine the subsequent most appropriate time intervals and the use of HPV screening test for subsequent monitoring of :
      o    Women in age to start screening, vaccinated  during adolescence
      o    Young women vaccinated two years before the start of screening.
•    To assess the feasibility and acceptance of the HPV vaccine by the women entering the routine screening between 25-45 years.

The results of the different components will be incorporated into transmission models, economic and impact made by the consortium to make projections of different preventive interventions.

The consortium is committed to producing systematic reviews that allow summarizing the evidence generated in the medical literature and contribute to the dissemination of research results.

CoheaHr consortium with the participation of twelve partners from eleven countries: Amsterdam, Barcelona, Tampere, London, Turin, Stockholm, Brussels, Ljubljana, Lyon, Copenhagen, Reims and Wolfsburg. The Research Program in Cancer Epidemiology ICO lead two areas of work, the study of acceptance of the vaccine in women aged 25-45 years and scientific dissemination activities.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!